- Home
- BIIB vs FTI Comparison
BIIB vs FTI Comparison
Compare BIIB & FTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BIIB
- FTI
- Stock Information
- Founded
- BIIB 1978
- FTI 1884
- Country
- BIIB United States
- FTI United States
- Employees
- BIIB N/A
- FTI N/A
- Industry
- BIIB Biotechnology: Pharmaceutical Preparations
- FTI Metal Fabrications
- Sector
- BIIB Health Care
- FTI Industrials
- Exchange
- BIIB Nasdaq
- FTI Nasdaq
- Market Cap
- BIIB 18.7B
- FTI 16.6B
- IPO Year
- BIIB 1991
- FTI N/A
- Fundamental
- Price
- BIIB $154.27
- FTI $41.35
- Analyst Decision
- BIIB Buy
- FTI Strong Buy
- Analyst Count
- BIIB 22
- FTI 11
- Target Price
- BIIB $174.11
- FTI $45.11
- AVG Volume (30 Days)
- BIIB 1.5M
- FTI 4.5M
- Earning Date
- BIIB 10-30-2025
- FTI 10-23-2025
- Dividend Yield
- BIIB N/A
- FTI 0.48%
- EPS Growth
- BIIB N/A
- FTI 59.09
- EPS
- BIIB 10.97
- FTI 2.28
- Revenue
- BIIB $10,065,900,000.00
- FTI $9,803,000,000.00
- Revenue This Year
- BIIB $2.03
- FTI $9.91
- Revenue Next Year
- BIIB N/A
- FTI $7.50
- P/E Ratio
- BIIB $14.06
- FTI $18.13
- Revenue Growth
- BIIB 4.77
- FTI 11.44
- 52 Week Low
- BIIB $110.04
- FTI $22.12
- 52 Week High
- BIIB $179.48
- FTI $42.65
- Technical
- Relative Strength Index (RSI)
- BIIB 64.58
- FTI 63.71
- Support Level
- BIIB $138.00
- FTI $35.29
- Resistance Level
- BIIB $151.91
- FTI $42.65
- Average True Range (ATR)
- BIIB 4.62
- FTI 1.25
- MACD
- BIIB 0.21
- FTI 0.53
- Stochastic Oscillator
- BIIB 94.70
- FTI 82.34
About BIIB Biogen Inc.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.
About FTI TechnipFMC plc
TechnipFMC is the largest provider of offshore oilfield services, offering integrated deep-water offshore oil and gas development solutions that span the full spectrum of subsea equipment and subsea construction services. The company also provides various pieces of surface equipment used with onshore oil and gas wells. TechnipFMC originated with the 2017 merger of Technip and FMC Technologies.